



S7 Fig. Anterior gradient 3 (AGR3) had no indication function for therapeutic response of doxorubicin, cyclophosphamide and methotrexate in breast cancer patients. (A) Overall survival (OS)

and progression-free survival (PFS) curves of AGR3 highly expressed invasive ductal carcinoma (IDC) patients with epirubicin or doxorubicin treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed IDC patients with epirubicin or doxorubicin treatment were shown, respectively (lower panel). (B) OS and PFS curves of AGR3 highly expressed IDC patients with cyclophosphamide treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed IDC patients with cyclophosphamide treatment were shown, respectively (lower panel). (C) OS and PFS curves of AGR3 highly expressed IDC patients with methotrexate treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed IDC patients with methotrexate treatment were shown, respectively (lower panel).